Tech Company Financing Transactions
Rallybio Funding Round
Rallybio, operating out of Farmington, secured $145 million from Pivotal bioVenture Partners, 5AM Ventures and Canaan Partners.
Transaction Overview
Company Name
Announced On
5/20/2020
Transaction Type
Venture Equity
Amount
$145,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from the financing will be used to advance Rallybio's current portfolio of product candidates targeting devastating rare diseases, including its lead program, RLYB211.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
400 Farmington Ave. R2818
Farmington, CT 06032
USA
Farmington, CT 06032
USA
Phone
Website
Email Address
Not Recorded
Overview
Rallybio is a privately-held early-stage biotechnology company incorporated in January 2018. Our ambition is to create a world-leading biotechnology organization that transforms the lives of patients with devastating disease, built around people with an outstanding track record in pharmaceutical research and development.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Co-Founder
Jeffrey Fryer
Co-Founder
Martin Mackay
Co-Founder
Stephen Uden
Browse more venture capital transactions:
Prev: 5/20/2020: Fountain Therapeutics venture capital transaction
Next: 5/20/2020: Encamp venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs